290 related articles for article (PubMed ID: 33320277)
1. Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study.
Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
Acta Derm Venereol; 2021 Jan; 101(1):adv00357. PubMed ID: 33320277
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
[TBL] [Abstract][Full Text] [Related]
3. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
4. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
Ziolkowska-Banasik D; Hadas E; Pastuszczak M
J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
[TBL] [Abstract][Full Text] [Related]
5. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.
Atalay S; van den Reek JMPA; van Vugt LJ; Otero ME; van de Kerkhof PCM; den Broeder AA; Kievit W; de Jong EMGJ
BMC Dermatol; 2017 May; 17(1):6. PubMed ID: 28482858
[TBL] [Abstract][Full Text] [Related]
6. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
7. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
8. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.
Schwarz CW; Loft N; Rasmussen MK; Nissen CV; Dam TN; Ajgeiy KK; Egeberg A; Skov L
Acta Derm Venereol; 2021 Oct; 101(10):adv00579. PubMed ID: 34642768
[TBL] [Abstract][Full Text] [Related]
11. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
12. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
13. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.
Loft N; Egeberg A; Isufi D; Rasmussen MK; Bryld LE; Dam TN; Ajgeiy KK; Bertelsen T; Skov L
Acta Derm Venereol; 2023 Nov; 103():adv12616. PubMed ID: 37987625
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
15. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
16. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Van Muijen ME; Thomas SE; Groenewoud HMM; Otero ME; Ossenkoppele PM; Njoo MD; Dodemont SRP; Kop EN; Berends MAM; Koetsier MIA; Mommers JM; Körver JEM; Tupker RA; De Bruin-Weller MS; Weppner-Parren LJMT; Peters B; Kleinpenning MM; Kuijpers ALA; Arnold WP; Van Lümig PPM; Van den Reek JMPA; De Jong EMGJ
Acta Derm Venereol; 2022 May; 102():adv00712. PubMed ID: 35356990
[TBL] [Abstract][Full Text] [Related]
17. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
Galluzzo M; Talamonti M; De Simone C; D'Adamio S; Moretta G; Tambone S; Caldarola G; Fargnoli MC; Peris K; Bianchi L
Expert Opin Biol Ther; 2018 Jul; 18(7):727-735. PubMed ID: 29798698
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
